Tetraphase Pharmaceuticals (NASDAQ:TTPH)

CAPS Rating: 4 out of 5

TTPH News and Commentary

Caps

How do you think TTPH will perform against the market?

Add Stock to CAPS Watchlist

All Players

57 Outperform
2 Underperform
 

All-Star Players

20 Outperform
0 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top TTPH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.58)
Submitted January 11, 2016

Tetraphase has been unusually volatile in the absence of catalysts since the September plunge on the IGNITE2 failure. The stock initially declined into the 7's, rebounded to the 11's, and is now back near cash in the low 7's. Some of that motion is… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

TTPH VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about TTPH.

Recs

0
Member Avatar rhallbick (96.98) Submitted: 5/4/2018 12:51:31 PM : Outperform Start Price: $3.11 TTPH Score: +31.67

Tetraphase Pharmaceuticals, Inc. (NASDAQ Global Select: TTPH)

New Drug Application (NDA) for their antibiotic Eravacycline was submitted to the FDA, and was accepted this past Feb for a substantive review. It was submitted for the treatment of complicated intra-abdominal infections (cIAI), and looks likely to be approved. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review is August 28.

Price: $3.11 | Annual Dividend: $0.00 | Dividend Yield: 0.00%

Recs

0
Member Avatar oscillation (76.83) Submitted: 1/16/2016 12:59:47 PM : Outperform Start Price: $5.60 TTPH Score: -68.64

nev

Recs

2
Member Avatar zzlangerhans (99.58) Submitted: 1/11/2016 9:28:11 AM : Outperform Start Price: $7.99 TTPH Score: -85.27

Tetraphase has been unusually volatile in the absence of catalysts since the September plunge on the IGNITE2 failure. The stock initially declined into the 7's, rebounded to the 11's, and is now back near cash in the low 7's. Some of that motion is likely related to instability in the broad markets, but I think it is also related to uncertainty regarding the company's short term plans for eravacycline. If the company decides to submit an eravacycline NDA for the narrow indication of cIAI this year, the stock could rise back into the teens. However, if they decide to run a new phase III before submission, the stock is probably dead money at best for the rest of the year. I think the risk/reward ratio starts to turn positive below 8, so I'm placing a green thumb and I'll be watching how the stock holds up if the sector retreat continues.

Leaderboard

Find the members with the highest scoring picks in TTPH.

Score Leader

pilotsdoithigh52

pilotsdoithigh52 (< 20) Score: +396.14

The Score Leader is the player with the highest score across all their picks in TTPH.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
IdahoInvestor 30.17 3/28/2013 Underperform 5Y $7.05 -39.72% +75.64% +115.36 0 Comment
whatthree16 68.24 9/14/2015 Underperform 5Y $8.83 -51.87% +39.41% +91.27 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. DeathStock 97.23 2/22/2018 Outperform 5Y $2.22 +91.44% +1.28% +90.17 0 Comment
DavidSobel < 20 2/27/2018 Outperform 5Y $2.84 +49.65% -1.19% +50.85 0 Comment
Paco57 46.67 3/8/2018 Outperform 3M $2.87 +48.08% +0.44% +47.65 0 Comment
tempttempt 72.96 2/27/2018 Outperform NS $2.99 +42.14% -1.28% +43.42 0 Comment
rhallbick 96.98 5/4/2018 Outperform NS $3.11 +36.66% +4.99% +31.67 1 Comment
clangmead 61.64 5/22/2018 Outperform 5Y $3.56 +19.38% +0.22% +19.16 0 Comment
portefeuille3 98.40 5/21/2018 Outperform 5Y $3.66 +16.12% +0.57% +15.55 0 Comment
portefeuille2 99.65 5/18/2018 Outperform 5Y $3.71 +14.71% +1.16% +13.55 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSunTrustRH 87.50 11/19/2015 Outperform NS $11.84 -64.10% +31.63% -95.73 0 Comment
TrackRWBaird 90.68 6/17/2014 Outperform NS $12.51 -66.03% +41.51% -107.54 0 Comment

Featured Broker Partners


Advertisement